Radiation plus a drug shrank hearing nerve tumors sooner
Original title: Longitudinal tumor response dynamics after staged gamma knife radiosurgery combined with bevacizumab in sporadic vestibular schwannoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked back at people already treated, so it is not yet proven as standard care.
The short version
In a look back at past records, tumors shrank sooner when a drug was added to radiation.
What was studied. Doctors reviewed records of 72 people with a tumor on the hearing and balance nerve. 49 had radiation given in stages plus a drug called bevacizumab: A drug that acts on the blood vessels a tumor builds. In brain tumors it is used mainly for two things. One is to control symptoms from swelling. The other is to cut down how much steroid someone needs. See the glossary. 23 had one session of radiation alone.
What they found. Tumors in the drug group shrank sooner and kept shrinking from 3 to 36 months. Early tumor swelling happened in 14.3% of the drug group, and in 60.9% of the radiation only group. Side effects from the drug were mild and easy to manage.
What this means, and what it doesn't
What it could mean: Adding this drug to staged radiation may help these tumors shrink sooner. It may also mean less early swelling, which can be scary to see on a scan. If you have this kind of tumor, you could ask your care team what they think.
What it doesn't mean: This does not mean the drug and radiation combination is proven. Doctors looked back at charts instead of running a planned, randomized trial. So the two groups may have differed in ways the study could not fix. This is not standard care today, and it is not a promise of a cure. Fewer people had false growth on scans, but that difference could be chance.
Source: PubMed, October 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.